NEDD8 and myelodysplastic syndrome: Several new agents have beendeveloped for MDS with the hopes of improving clinical outcomes and survival.Pevonedistat is a first-in-class, novel inhibitor of neuronal precursorcell-expressed developmentally down-regulated protein-8 (NEDD8) activatingenzyme (NAE) blocking the neddylation pathway leading to downstream effects onthe ubiquitin–proteosome pathway.